STOCK TITAN
  1. Home
  2. News
  3. SRRK

Scholar Rock Holding Corp - SRRK STOCK NEWS

Welcome to our dedicated news page for Scholar Rock Holding (Ticker: SRRK), a resource for investors and traders seeking the latest updates and insights on Scholar Rock Holding.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Scholar Rock Holding's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Scholar Rock Holding's position in the market.

News
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Scholar Rock (SRRK) grants inducement equity awards to new employees under Nasdaq Listing Rule 5635(c)(4), covering 45,000 shares of common stock. The awards consist of stock options and restricted stock units, with specific vesting schedules. The company aims to attract and retain top talent through these inducement grants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.89%
Tags
management
-
News
Scholar Rock Reports Full Year 2023 Financial Results and Highlights Business Progress
Rhea-AI Summary
Scholar Rock (SRRK) reported significant progress in its Phase 3 SAPPHIRE trial for Spinal Muscular Atrophy (SMA) and received FDA clearance for a Phase 2 trial with apitegromab for obesity. The company ended 2023 with $280 million in cash, poised for a transformative year ahead.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.77%
Tags
earnings
-
News
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Scholar Rock (SRRK) grants inducement equity awards totaling 201,469 shares to newly hired employees. The awards consist of stock options and restricted stock units under the 2022 Inducement Equity Plan. The options have exercise prices of $15.06 and $16.28, with vesting conditions tied to employee service.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.65%
Tags
management
News
Scholar Rock to Participate in Upcoming Investor Conferences
Rhea-AI Summary
Scholar Rock (SRRK) announces its participation in upcoming investor conferences in March, including TD Cowen 44th Annual Health Care Conference, 3rd Annual Jefferies Biotech on the Bay Summit, and BMO Biopharma Spotlight Series: Obesity Day. The company aims to advance innovative treatments for spinal muscular atrophy (SMA) and other serious diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.76%
Tags
conferences
-
News
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Scholar Rock (SRRK) grants inducement equity awards to new employees, totaling 131,688 shares of common stock, including stock options and restricted stock units. The awards are part of the 2022 Inducement Equity Plan, with options priced at $15.75 and vesting over time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
News
Scholar Rock Announces the Addition of Katie Peng to Its Board of Directors and Promotes Mo Qatanani, Ph.D. to Chief Scientific Officer
Rhea-AI Summary
Scholar Rock (SRRK) appoints Katie Peng to Board of Directors and promotes Mo Qatanani to Chief Scientific Officer. Peng brings extensive commercial experience in neurology and rare diseases. Qatanani has a strong background in discovery and translational research. The company is preparing for the potential launch of apitegromab next year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.74%
Tags
management
News
Scholar Rock Presents New Preclinical Data Demonstrating Potential Benefit of SRK-439 for Healthy Weight Loss Management
Rhea-AI Summary
Scholar Rock (SRRK) presented preclinical findings at Keystone Symposia showing lean mass preservation, fat mass loss, and improved glucose metabolism with their novel myostatin inhibitor, SRK-439. The data suggests potential for SRK-439 to preserve lean mass and improve metabolic health in healthy weight loss management, with a proof-of-concept study planned for mid-2024. The company also announced FDA clearance for a Phase 2 trial of apitegromab to treat obesity, with trial initiation expected in mid-2024 and data in mid-2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.45%
Tags
clinical trial
-
News
Scholar Rock Announces Presentation of New Preclinical Data Evaluating SRK-439 in Obesity at Keystone Symposia
Rhea-AI Summary
Scholar Rock (NASDAQ: SRRK) announced preclinical data evaluating SRK-439, a selective myostatin inhibitor, for the treatment of cardiometabolic disorders. The data supports the potential of SRK-439 to preserve lean muscle mass during healthy weight loss. The company will present its findings at the Keystone Symposia’s Obesity: Causes and Consequences meeting in February 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.15%
Tags
clinical trial
-
News
Scholar Rock Announces FDA Clearance of IND Application to Initiate Phase 2 Proof-of-Concept Trial with Apitegromab to Treat Obesity
Rhea-AI Summary
Scholar Rock (NASDAQ: SRRK) announced that the FDA has cleared the company’s Investigational New Drug application for its Phase 2 proof-of-concept trial of apitegromab to treat obesity in patients taking a GLP-1 receptor agonist. The study aims to evaluate the effect of apitegromab, a highly selective myostatin inhibitor, in preserving lean muscle mass as an adjunctive therapy in overweight and obese adults. The Phase 2 trial is set to initiate in mid-2024, with data expected in mid-2025. Scholar Rock is also developing SRK-439, a novel investigational selective myostatin inhibitor, optimized for the treatment of obesity and plans to file an IND for SRK-439 in 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.29%
Tags
clinical trial
News
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Scholar Rock (SRRK) announced the granting of inducement equity awards to a newly hired employee, covering 26,250 shares of its common stock. The awards consist of stock options and restricted stock units, subject to the terms of the company's 2022 Inducement Equity Plan. The options have an exercise price of $17.08 and will vest over time, with 25% vesting after the first year and the remaining 75% in quarterly installments. RSUs will vest in four equal annual installments, all subject to the employee's continued service at the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
Stock SRRK logo
Scholar Rock Holding Corp

Nasdaq:SRRK

SRRK Rankings

#2349 Ranked by Market Cap
#1614 Ranked by Stock Gains
N/A Ranked by Dividends

SRRK Stock Data

1.05B
48.17M
2.25%
106.94%
16.08%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Cambridge

About SRRK

scholar rock® is a biotechnology company focused on discovering and developing a new class of biologic therapies called "niche modulators" that selectively target the activation of growth factors in the disease microenvironment. our initial proprietary and partnered drug discovery programs target specific growth factors, including members of the tgf-beta superfamily, which play a fundamental role in regulating cell growth and differentiation and are present in the microenvironments of significant diseases such as fibrosis, diseases of the musculoskeletal systems, and autoimmune diseases. the company’s therapeutic approach is enabled by discoveries made by scholar rock’s scientific founders—professors timothy springer, phd, and leonard zon, md, both of children's hospital boston and harvard medical school—related to the molecular mechanisms of growth factor activation. scholar rock is backed by leading life sciences investors, including polaris partners, arch venture partners, timothy s